Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder

- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)
- In the Phase III trial, most patients experienced a sustained decrease in mean urinary-free cortisol levels, a key measure of disease, with a subset normalizing(2)
- In the EU, Signifor has been previously approved for the treatment of adult patients with Cushing's disease; other worldwide regulatory filings are underway

(0)

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP